[BioS] CrossPoint Signs MOU with Samyang Biopharm to Develop Anticancer siRNA
Predicted impact: Low
Non-binding MOU for early-stage anticancer siRNA development; no financial terms or revenue size disclosed.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.